Gilead Sciences Finally Starts Succeeding:
Gilead Sciences has new businesses and milestones planned for 2024. Click here to read the full investment analysis of ...
seekingalpha.com/article/4679557-gilead-sciences-finally-starts-succeeding
Paid articlePaywallStory Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
Similar to This
Previous
STAT Nov 03
Who will get the first psychedelic approved?: Today's biotech news examines Gilead's HIV prevention shot goes generic, Bright Minds' seizure drug ...
statnews.com/2026/11/03/biotech-news-who-will-get-the-first-psychedelic-approved/
Paid articlePaywall
Barron's Mar 31 25
Moderna Stock Sinks After Top FDA Official Resigns; Sarepta Gets Hit, Too.: Dr. Peter Marks, who led the FDA’s Center for Biologics Evaluation and Research ...
barrons.com/articles/fda-resignation-peter-marks-biotech-stocks-9a19c2cb
Paid articlePaywall Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +
seekingalpha.com/article/4719568-undercovered-dozen-epr-properties-gilead-portland-general-electric-cnh-industrial-plus
Paid articlePaywall Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices: Gilead Sciences reported good quarterly results and in the last few weeks ...
seekingalpha.com/article/4718517-gilead-sciences-might-finally-be-on-its-way-to-higher-stock-prices
Paid articlePaywall Gilead Sciences: The Upcycle Is Just Getting Started: Learn why Gilead Sciences is a strong buy with promising growth potential in key drug franchises and an ...
seekingalpha.com/article/4706002-gilead-sciences-the-upcycle-is-just-getting-started
Paid articlePaywall Cassava Sciences: A 'Moon Shot' Becomes A Bigger 'Long Shot': Cassava Sciences, Inc., which has a late-stage candidate targeting Alzheimer's ...
seekingalpha.com/article/4702068-cassava-sciences-a-moon-shot-becomes-a-bigger-long-shot
Paid articlePaywall Gilead Sciences: Strategic Gains From Lenacapavir And Trodelvy Justify A Buy Rating
seekingalpha.com/article/4700693-gilead-sciences-strategic-gains-from-lenacapavir-and-trodelvy-justify-a-buy-rating
Paid articlePaywall Gilead Records Positive Phase III Results In HIV: Gilead Sciences' groundbreaking lenacapavir trial results could transform HIV prevention and treatment ...
seekingalpha.com/article/4700481-gilead-records-positive-phase-iii-results-in-hiv
Paid articlePaywall Gilead Sciences: Seriously Undervalued At Peak Pessimism: Gilead Sciences published financial results for the first quarter of 2024, which were better than I ...
seekingalpha.com/article/4696051-gilead-sciences-seriously-undervalued-at-peak-pessimism
Paid articlePaywall Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?: Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25 ...
seekingalpha.com/article/4685264-gilead-q1-earnings-preview-most-gains-wiped-out-cause-for-concern
Paid articlePaywall Gilead Sciences: Cheap For A Reason: Gilead Sciences reported its Q4 2023 results, which paint a picture of a stagnant company. Read why GILD stock is a hold.
seekingalpha.com/article/4669249-gilead-sciences-cheap-for-a-reason
Paid articlePaywall Without A Clear Growth Path, Gilead Sciences Is A Hold: Gilead Sciences has seen stagnant sales growth over the past decade, but has potential for future growth ...
seekingalpha.com/article/4660512-without-a-clear-growth-path-gilead-sciences-stock-is-a-hold
Paid articlePaywallGuess how much big pharma paid in US taxes on $110 billion of profit in 2022: Pfizer, Merck, J&J, Gilead, Eli Lilly, Amgen BMS, and AbbVie paid a combined $2 ...
qz.com/guess-how-much-big-pharma-paid-in-us-taxes-on-110-bill-1850441135
Paid articlePaywall
Why governments are snooping on sewage: Our podcast on science and technology. This week, we explain how wastewater surveillance could offer an unprecedented ...
economist.com/podcasts/2022/10/04/why-governments-are-snooping-on-sewage
How artificial intelligence cracked biology’s biggest problem: Our podcast on science and technology. This week, we examine how DeepMind’s AI system predicted ...
economist.com/alphafold-pod
Paid articlePaywallRecession stars: The best stocks in every industry during economic downturns: CNBC Pro found the best performers in each industry as predictions of a recession ...
cnbc.com/2022/06/29/recession-stars-the-best-stocks-in-every-industry-during-economic-downturns.html
Paid articlePaywall How can corals withstand ever-warming seas?: Our science and technology podcast. This week, we explore how scientists are trying to harness the properties of ...
economist.com/news/2022/05/31/how-can-corals-withstand-ever-warming-seas
CureVac’s COVID vaccine has important role to play in fighting variants, CEO says
marketwatch.com/story/curevacs-covid-vaccine-has-important-role-to-play-in-fighting-variants-ceo-says-11622038618
Coronavirus: Italian paper on origins of pandemic hit by backlash from scientists
scmp.com/news/china/science/article/3110576/coronavirus-italian-paper-origins-pandemic-hit-backlash
Paid articlePaywall Next